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A B S T R A C T
BACkgRound: prognosis of cancer patients requiring invasive mechanical ventila-
tion (imv) is poor. various studies conducted mainly in patients with haematologi-
cal malignancies have shown that Non-invasive ventilation (Niv) is associated with 
improved results
oBjeCTive: to compare Niv with imv in patients with various malignancies. an 
assessment was also made of the possible bias in our results due to recent improve-
ments in imv.
MATeRiAl And MeThodS: a historically matched controlled study of Niv versus 
imv. Forty seven patients treated by Niv were matched with 47 historical controls 
treated by imv. matching was performed according to 5 variables: type of cancer, 
leucopenia, allogeneic bone marrow transplantation, saps ii score and reason for 
ventilation.
ReSulTS: duration of ventilation and of hospitalisation were significantly (p=0.001) 
shorter in the Niv group; 48% of patients treated with Niv were discharged from the 
hospital versus 23% of those treated by imv (p=0.08). Niv was statistically more 
effective than imv in solid tumours, non transplanted and non leucopenic patients. 
contrary to the period before 1996, when the analysis was restricted to the imv 
matched cases, in the period since 1996, no difference in terms of mortality between 
imv and Niv was found.
ConCluSionS: in comparison with imv, Niv in cancer patients: is associated with 
two significant advantages: reduction in ventilation duration and reduction in hospi-
talisation stay.
i n T R o d u C T i o n
during the last decade, Non-invasive ventilation (Niv) has been increasingly used 
for the management of respiratory failure in the icu. it is currently considered as the 
preferred initial treatment for acute exacerbation of chronic obstructive pulmonary 
disease [1], for acute haemodynamic oedema [2] and for acute hypoxaemic respiratory 
failure occurring in immunocompromised patients [3,4]. in cancer patients, Niv has 
been shown in two case-control studies [5,6] to be associated with improved results 
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when compared to invasive mechanical ventilation (imv). 
in both, the majority of the patients had haematological 
malignancies and the study design was retrospective, using 
historical controls. Nonetheless, azoulay et al [5] have also 
observed improved results in imv patients treated in the 
more recent period (after 1996) when compared to patients 
treated before 1996.
in a preliminary study [7], we reported our own experi-
ence, showing that in a random cancer patients population, 
Niv was an effective form of ventilatory support, with a 
58% and 43% discharge rate from the icu and the hospital, 
respectively. these results appeared very encouraging, and 
they compared favourably to those reported in oncological 
patients treated with imv [8], including our own, where, 
in a series of 168 cancer patients, we were able to extubate 
26%, and discharge 22% from the icu and 17% from the 
hospital [9]. yet such good results render ethically unjustifi-
able the performance of a randomised trial to demonstrate 
the superiority of starting intensive care management with 
Niv versus imv in cancer patients. these considerations 
led us to perform a historically matched controlled study in 
order: 1) to determine if Niv, as opposed to imv, results in 
a better outcome for cancer patients with solid tumours and 
haematological malignancies, and 2) to assess if the improved 
results with Niv reported in the literature were not explained 
by a less effective intensive care management in the early imv 
period (before 1996).
M A T e R i A l  A n d  M e T h o d S
potential candidates for the present study were patients 
requiring mechanical ventilation in the medical icu of our 
cancer hospital, between November 1985 and april 2004. to 
be eligible, cancer patients had to have respiratory failure, 
defined as: severe dyspnoea at rest; profound hypoxaemia 
in room air or during nasal oxygen therapy and/or severe 
hypercapnia; acute pulmonary haemodynamic oedema non-
responding rapidly to diuretics and oxygen; clinical decision 
that the patient required support with mechanical ventila-
tion. patients without underlying neoplastic disease and/or 
admitted for elective surgery were ineligible. patients with 
“dNr” (“do not resuscitate”) orders were excluded because, 
by definition in our hospital, they are not eligible for imv. 
patients who were intubated for cardio-respiratory arrest, for 
haemodynamic instability, and/or with a Glasgow scale score 
for coma <8 were ineligible because they were considered as 
absolute indications for imv. patients with excessive secre-
tions, agitation, inadequate cooperation or severely impaired 
mental status were also excluded from the Niv group. in case 
of multiple admissions for a given patient, only the first episode 
of ventilation was taken into account. No ethics approval was 
required for this historically matched controlled study.
every Niv patient was matched with a corresponding imv 
patient for 5 variables: type of cancer (solid tumour versus 
haematological tumour); allogeneic bone marrow or stem 
cell transplantation (yes versus no); leucopenia (white blood 
cell count <1000/mm³ versus ≥1000/mm³) at icu admission; 
equivalent gravity score (saps ii) at admission (equivalence 
defined as an absolute difference £5); reason for ventilation 
(hypoxaemic respiratory failure versus hypercapnic respiratory 
failure versus acute pulmonary haemodynamic oedema).
the following information was retrospectively retrieved 
from the medical chart of each patient: demographic data at 
icu admission (age, gender); characteristics of the disease: 
type of cancer, time since diagnosis, prior treatment, includ-
ing bone marrow or stem cell transplantation, cancer phase 
[10] (diagnostic, curative, controllable but no more curable, 
pivotal or palliative care; patients at palliative stage should not 
be admitted for critical care under our icu policy), leukocyte 
count at icu admission (leucopenia was defined as a leuko-
cyte count <1000 cells/mm³); reason for icu admission and 
reason for mechanical ventilation; saps ii scores calculated 
on the basis of the most disturbed value recorded during the 
first 24 hours of stay after icu admission; period of icu 
admission; duration of ventilation and of icu hospitalisation; 
icu and hospital discharge.
imv was performed with the servo ventilator (siemens, 
solna, sweden) or with the evita 4 ventilator (dräger, lübeck, 
Germany). Niv, available since January 2000 in our institu-
tion, was provided with a standard facial mask by the Bipap 
vision ventilator (respironics inc, murrysville, usa). positive 
end expiratory pressure (between 3 and 11 cm h2o), pressure 
support (between 7 and 24 cm h2o) and Fio2 were adjusted 
to patient’s tolerance and to arterial blood gases. Niv was 
used for a minimum of 1 hour every 4 hours but sometimes 
continuously, if necessary, to maintain blood arterial haemo-
globin oxygen saturation > 90%. When the patient’s condition 
improved, we progressively weaned Niv by 2 cm h2o decre-
ments over a few hours. patients who failed Niv underwent 
tracheal intubation and were mechanically ventilated. criteria 
for endotracheal intubation included persistence of respira-
tory failure or haemodynamic instability, but also the need to 
protect the airways to manage copious tracheal secretions or 
alveolar bleeding and intolerance to mask ventilation.
on the basis of our previous studies [7,9], we have calcu-
lated that we needed to have 51 patients by arm to show that 
Niv allows improvement of success rate (discharge from icu) 
to 50% from an expected imv success rate of 20% with a 
statistical power of 90% and an α error risk of 5% (two-tailed 
comparison). our study was stopped after the recruitment 
of 47 patients in each arm. indeed as Niv seemed effective, 
we used it more and more as first choice for ventilation. 
therefore, the problem was that, to obtain further patients 
to match, we needed to consider patients treated as controls 
over too long a period. it should be noted that during this 
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period, 17 patients with dNr order were treated by Niv, but 
were excluded from the present study according to our above 
mentioned criteria.
macNemar tests were used to compare matched observa-
tions for binary outcomes. paired Wilcoxon tests were used to 
compare continuous variables. Fisher test was used to compare 
categorical variables. to adjust the comparison of the two 
intervention strategies for covariates that had a significant 
impact on the probability of death, we used logistic regres-
sion models with estimation of odd ratios and calculation of 
95% confidence intervals. a p value < 0.05 was considered 
as statistically significant. 
R e S u l T S
patients’ characteristics including demography, neoplastic 
disease and respiratory failure requiring ventilatory support 
are described in table 1. a patient in the Niv group, pre-
sented with renal adenocarcinoma who benefited from an 
allogeneic bone marrow transplantation, was considered as 
equivalent to transplanted haematological patients in terms 
of immunosuppression and matched with a haematological 
patient. two haematological patients had autologous marrow 
transplantation; in each group they were matched with non- 
transplanted haematological patients. twenty-four patients 
in the Niv group were included in our previous report [7], 
which was only a feasibility study about the place of Niv in 
cancer patients (enrolment until November 2001). ventilatory 
support was provided during the first 24h icu admission in 
33 patients in the Niv cohort and 22 in the imv one. about 
40% of the matched patients had haematological malignancies 
and 60% solid tumours. 
results obtained by both techniques are shown in table 2. 
duration of ventilation support was shorter (p=0.001) with 
Niv than with imv. icu hospitalisation stay was significantly 
(p=0.01) reduced in the Niv group. twenty-six patients 
(55.3%) in the Niv group and 13 patients (27.6%) in the 
imv group were discharged alive from the icu (p=0.01). 
twenty-three patients (48.9%) in the Niv group and 11 
(23.4%) patients in the imv group were discharged alive 
from the hospital (p=0.08). 
subgroup analyses are shown in table 3 for icu discharge 
and in table 4 for hospital discharge. Niv was particularly 
effective in the non-leucopenic, non- allo-transplanted and 
solid tumours subgroups as well as in the subgroup of patients 
matched with controls treated before 1996. median duration 
of ventilation support for the subgroup matched with controls 
treated before 1996, was 2.5 days (range: 1- 26) with Niv 
and 10.5 days (0 – 47) with imv (p=0.004), respectively and 
for the subgroup matched with controls treated since 1996, 3 
days (range: 1 – 24) with Niv and 10 days (0 – 36) with imv 
(p=0.008), respectively. median duration of icu stay for the 
subgroup matched with controls treated before 1996, was 10 
days (range: 1- 42) with Niv and 15.5 days (1 – 47) with imv 
(p=0.28), respectively and for the subgroup matched with 
controls treated since 1996, 8 days (range: 1 – 26) with Niv 
and 19 days (1 – 172) with imv (p=0.02), respectively.
among the patients in the Niv group, 15 (31.9%) required 
endotracheal intubation after failure of Niv and only one of 
them was discharged alive from icu and hospital. reasons 
for intubation were persistence of respiratory failure (n=6), 
septic shock (n=4), abundant alveolar haemorrhage (n=3) 
and alteration of consciousness (n=2).
TABle 1. patients characteristics.
Arm niv iMv
Gender
 - male
 - female
28 (59.6%)
19 (40.4%)
31 (66.0%)
16 (34.0%)
age (years) - median (range) 56 (23-78) 56 (23-79)
type of tumour
1) solid tumours
 - lung cancer
 - other
2) haematologic malignancies
 - acute leukaemia
 - other
29 (61.7%)
13 (27.6%)
16 (34 %)
18 (38.3%)
10 (21.3%)
8 (17 %)
28 (59.6%)
12 (25.5%)
16 (34 %)
19 (40.4%)
13 (27.6%)
6 (12.7 %)
cancer phase
- diagnostic
- curative
- control
- pivotal
2 (4.3%)
22 (46.8%)
22 (46.8%)
1 (2.1%)
4 (8.5%)
20 (42.6%)
17 (36.2%)
6 (12.8%)
cancer duration (months)
- median (range) 11 (0-156) 12 (0-180)
allogeneic bone marrow or stem 
cell transplantation
9 (19.1%) 9 (19.1%)
leucopenia (<1000/mm³) 10 (21.3%) 10 (21.3%)
leukocyte level (mm³)
- median (range) 5790
(10-42370)
8400
(0-79500)
saps ii
- median (range) 34 (16-64) 34 (16-66)
cause requiring mechanical 
ventilation
- hypoxemic respiratory failure
- hypercapnic respiratory 
failure
- acute haemodynamic oedema
34 (72.3%)
10 (21.3%)
3 (6.4%)
34 (72.3%)
10 (21.3%)
3 (6.4%)
median pao2 (range) in mm hg 55 (33-93) 67 (43-200)
median paco2 (range) in mm hg 37 (18-88) 43 (28-69)
median ph (range) 7.39 (7.18-7.54) 7.36 (7.00-7.53)
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TABle 2. overall results according to variation out-
comes.
outcome
Arm
pniv iMv
ventilation duration (days)
   - median (range) 3 (1-26) 10 (0-47) 0.001
icu hospitalisation stay 
(days)
   - median (range) 9 (1-42) 16 (1-91) 0.01
icu discharge 26 (55.3%) 13 (27.6%) 0.01
hospital discharge 23 (48.9%) 11 (23.4%) 0.08
TABle 3. subgroup analyses for icu discharge.
Subgroup
Arm
p
niv iMv
n pts % discharge n pts % discharge
solid tumours 29 69 28 28.6 0.02
haematological malignancies 18 33.3 19 26.3 0.63
leucopenic patients 10 10.0 10 20.0 1
Non leucopenic patients 37 67.5 37 29.7 0.004
allo-transplanted patients 9 22.2 9 22.2 1
Non allo-transplanted patients 38 63.1 38 28.9 0.004
hypoxemic respiratory failure 34 47.0 34 20.6 0.02
hypercapnic respiratory failure 10 90 10 40.0 0.13
acute haemodynamic oedema 3 66.6 3 66.6 Na
matching with controls treated before 1996 26 61.5 26 11.5 0.004
matching with controls treated since 1996 21 47.6 21 47.9 1
By logistic regression, we found that the probability of 
death in icu was higher in the patients treated with imv 
performed before 1996 (or=10.86; 95% ci: 2.75-42.80; 
p=0.001) and in leucopenic patients (or=6.38; 95% ci: 1.62-
25.09; p=0.008). By the same method, we observed that the 
probability of death in hospital was also higher in the patients 
treated with imv performed before 1996 (or=7.91; 95% ci: 
2.03-30.72; p=0.003) and in leucopenic patients (or=4.53; 
95% ci: 1.16-17.62; p=0.03). the type of tumour, the type of 
respiratory failure, imv performed after 1996 and the pres-
ence of bone marrow transplantation were not identified as 
independent prognostic factors. 
d i S C u S S i o n
The present case-control study shows that non-invasive 
ventilation results in two significantly important advantages 
for cancer patients with respiratory failure : shorter ventilation 
duration and shorter ICU stay. Hospital and ICU discharge 
rates are significantly improved only when historical controls 
before 1996 are used for the invasive mechanical ventilation 
matched cases.
Our data are consistent with those already published in 
the haematological literature [5,6]. In his retrospective study, 
Azoulay et al. [5] found that NIV, ICU admission after 1995 
and SAPS II score were significantly favourable independent 
predictors of 30-day mortality in a series of 237 mechanically-
ventilated cancer patients. We have also observed that patients 
treated with IMV before 1996 also had a significantly poorer 
survival. Depuydt et al. matched 48 NIV subjects with 48 IMV 
cases and obtained crude ICU mortality rates of 43.7% and 
70.8%, respectively [6]. This difference remained significant 
after adjustment for matching variables (including period of 
ICU admission). Although we found comparable rates in the 
overall population, our results were similar to those reported 
by Depuydt et al, when the analysis was performed in the sub-
group of more contemporary controls. Depuydt [6] performed 
a retrospective study in a series of 168 consecutive patients 
with haematological malignancies and acute respiratory failure 
requiring mechanical ventilation. Accrual started in 1997. He 
matched 27 patients who received NIV with 52 patients who 
required IMV and found a crude in-hospital mortality rate of 
65.4% in both groups, which is in the same range of the results 
we obtained when using the more contemporary controls.
Our patient population had a different case-mix, with the 
majority of patients with a solid tumour, contrary to the two 
other published case-control studies. Depuydt had only haema-
tological malignancies and Azoulay et al. only a small minority 
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of solid tumours (12.5%). Published data on NIV in patients 
with solid tumours are so far limited : one case of dynamic large 
airway obstruction associated with lung cancer [11], six cases 
in each arm of the case-control study by Azoulay et al. [5] and 
two lung cancer patients who refused intubation [12]. 
There are also differences in the matched variables. For 
our study, we used 5 variables (type of cancer, bone marrow or 
stem cell allotransplantation, leucopenia, SAPS II and reason 
for ventilation). Azoulay et al. matched for 3 variables (type of 
cancer, reason for ventilation and period of ICU admission) and 
Depuydt for one only (SAPS II). We used SAPS II because it 
was in our experience the most important prognostic factor in 
cancer patients admitted in ICU [13], leucopenia because it was 
a pejorative independent prognostic factor in our population 
when IMV was required [9] and allogeneic transplantation 
because of the particular poor prognosis in case of respiratory 
failure [14,15].
a limitation of our study is related to its methodology 
(case-control with historical controls). We had to use historical 
controls because the selection of contemporary cases for imv 
in our data basis would have been potentially highly biased 
due to the rapid extensive application of Niv in our practice 
since the technique became available. the main problem 
resulting from that approach is related to the improvement 
of care and results of imv in general intensive care [16,17] 
and also in critical care of haemato-oncological patients, as 
already shown by azoulay [18]. a better level of evidence 
would be obtained by performing randomised studies testing 
Niv versus imv allowing, in a second time, meta-analyses as 
available for acute exacerbation of chronic obstructive pulmo-
nary disease [19,20], acute hypoxaemic respiratory failure [21] 
or weaning strategy [22]. such a scientific approach is today 
extremely difficult to be adopted because of the very poor 
base-line prognosis of cancer patients requiring mechanical 
ventilation and the encouraging results obtained by Niv in this 
situation. there is only one relatively small randomised trial 
available [4], performed in immunosuppressed patients (with 
a majority of haematological malignancies) with pulmonary 
infiltrates, fever and acute respiratory failure. the administra-
tion of intermittent Niv was shown to result in significantly 
reduced intubation and mortality rates when compared to 
conventional care with supplemental oxygen. a randomised 
trial with a similar design and objective has been conducted 
in patients undergoing solid organ transplantation [3]. Niv 
resulted in significant reduction of intubation, length of stay 
in icu and icu mortality (but not hospital mortality). those 
studies, as well as the case-control studies already mentioned, 
and the very significant patients’ advantages, such as shorter 
duration of ventilation support, icu stay and hospitalisation 
(confirmed in our own study), have led to the widespread 
application of Niv, with guidelines recommending Niv as 
initial mode of ventilation support for this type of patients, 
even in case of ards [23].
C o n C l u S i o n S
In comparison to IMV, the administration of NIV for re-
spiratory failure in cancer patients is associated with important 
benefits such as reduction in ventilation support duration and 
in ICU and hospitalisation stay. The impact on mortality is not 
evident when patients are matched with more contemporary 
TABle 4. subgroups analyses for hospital discharge.
subgroup
arm
p
Niv imv
N pts % discharge N pts % discharge
solid tumours 29 58.6 28 21.4 0.01
haematological malignancies 18 33.3 19 26.3 0.63
leucopenic patients 10 10.0 10 20.0 1
Non leucopenic patients 37 59.5 37 24.3 0.002
allo-transplanted patients 9 22.2 9 22.2 1
Non allo-transplanted patients 38 55.3 38 23.6 0.002
hypoxemic respiratory failure 34 41.2 34 20.5 0.07
hypercapnic respiratory failure 10 80.0 10 30.0 0.06
acute haemodynamic oedema 3 33.3 3 33.3 Na
matching with controls treated before 1996 26 50.0 26 11.5 0.005
matching with controls treated since 1996 21 47.6 21 38.1 0.75
98
hospital chroNicles 1(2), 2006
controls treated since 1996. The obtained benefits, confirmed 
by other similar studies, render the performance of randomised 
trials to obtain a higher level of evidence for recommendations 
ethically difficult. Further developments of NIV may occur 
with the use of helmet instead of facial mask [24,25] and with 
the application of ventilation support in cancer patients with 
limitations for invasive life-support techniques [26].
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